January 20, 2023Clinical Infectious Diseases138 citationsOpen Access

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

EOEdgar T. Overton GRGary Richmond GRGiuliano Rizzardini

Key Points

Key points are not available for this paper at this time.

Abstract

These data demonstrate virologic suppression durability with CAB+RPV LA Q8W or Q4W for ∼3 years and confirm long-term efficacy, safety, and tolerability of CAB+RPV LA as a complete regimen to maintain HIV-1 virologic suppression.

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Overton et al. (2023) studied this question.

synapsesocial.com/papers/69d93c7bed2e131d3c68406c https://doi.org/10.1093/cid/ciad020

Ask AI

Helpful

Bookmark

View Full Paper

January 20, 2023Clinical Infectious Diseases138 citationsOpen Access

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

View Full Paper

EOEdgar T. Overton GRGary Richmond GRGiuliano Rizzardini

Key Points

Key points are not available for this paper at this time.

Abstract

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Overton et al. (2023) studied this question.

synapsesocial.com/papers/69d93c7bed2e131d3c68406c https://doi.org/10.1093/cid/ciad020

Ask AI

Helpful

Bookmark

View Full Paper